Plain-English translation of NCT06822738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new device called XEN63—a tiny gel stent that is implanted in the eye to help lower eye pressure in people with glaucoma. Researchers want to compare two different surgical approaches for placing this implant: one that goes through the inside of the eye and one that goes through the outside. The study will follow about 130 participants for one year to see how safe and effective this treatment is.
Glaucoma is a leading cause of blindness worldwide, and some patients don't respond well enough to eye drops and other standard treatments. This medication is being tested to give people who have failed other treatments a new option to lower the pressure in their eyes and help prevent vision loss.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a minor surgical procedure to implant the gel stent in your eye on day one. You'll then visit the clinic regularly over 12 months for check-ups and eye exams to make sure the implant is working safely and lowering your eye pressure as expected. Researchers will monitor you closely to catch any side effects early and measure how well this treatment is working for your glaucoma.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
United States